Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
CNTA
$26.8112
$
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B. The company also has emerging pipeline products under clinical proof of concept stage comprising LB101, a PD-L1xCD47 LockBody, as well as LB201, a PD-L1xCD3 LockBody, which are designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874, a small molecule pharmacological chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase I clinical development for the treatment of alpha-1-antitrypsin deficiency; MGX292, a recombinant modified BMP9 replacement protein designed to overcome the deficiency in BMP9 signaling in Pulmonary Arterial Hypertension; and OX2R Agonists that are oral and intranasal selective orexin receptor 2 agonists designed to leverage structural insights and to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1. In addition, the company has exploratory pipeline products under clinical proof of concept stage containing CBS001, an anti-LIGHT antibody, which preferentially binds the inflammatory membrane form of LIGHT in inflammatory/fibrotic diseases; and CBS004, a humanized mAb specific to BDCA2, expressed exclusively on plasmacytoid dendritic cells in systemic sclerosis, systemic lupus erythematosus, and other autoimmune diseases. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.
Next Earnings
2026-02-25
Beta
1.572
Average Volume
Market Cap
Last Dividend
CIK
0001847903
ISIN
US1523091007
CUSIP
152309100
CEO
Mario Alberto Accardi
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
77
IPO Date
2021-05-28
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Biotech Fund Dumps 1.85 Million Centessa Shares as Stock Jumps Over 50% | Commodore Capital sold 1,850,000 shares of Centessa in the fourth quarter; the estimated trade value was $46.86 million. Meanwhile, the quarter-end position value decreased by $44.10 million, reflecting both trading and price changes. | The Motley Fool | 2026-02-23 10:09:48 |
| This Fund Just Disclosed a New $55 Million Bet on Centessa Amid 53% Stock Rally and CEO Transition | Connecticut-based Braidwell initiated a position of 2,188,320 Centessa shares in the fourth quarter. The quarter-end value of the position increased by $54.73 million, reflecting the new stake. | The Motley Fool | 2026-02-19 17:03:28 |
| Nxera Pharma to Receive $1.8 Million Milestone Payment from Centessa Pharmaceuticals | Tokyo, Japan and Cambridge, UK, 12 February 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today notes that Centessa Pharmaceuticals has achieved an early development milestone associated with its investigational, orally administered, highly potent and selective orexin receptor 2 (OX2R) agonist, ORX489, being developed by Centessa for the treatment of neuropsychiatric disorders. This milestone triggers a payment of US$1.8 million to Nxera pursuant to its research collaboration with Centessa. The milestone payment will be recognized as revenue in the first quarter of 2026. | GlobeNewsWire | 2026-02-12 03:45:00 |
| Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences | BOSTON and LONDON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences: Event: Guggenheim Emerging Outlook: Biotech Summit Date: Thursday, February 12, 2026 Fireside Chat: 1:00 PM ET Event: TD Cowen 46th Annual Health Care Conference Date: Tuesday, March 3, 2026 Fireside Chat: 3:10 PM ET Event: Leerink Partners Global Healthcare Conference Date: Tuesday, March 10, 2026 Fireside Chat: 8:00 AM ET Event: Jefferies Biotech on the Beach Summit Date: Wednesday, March 11, 2026 Where available, access to the live webcasts of these events, as well as archived recordings, will be posted under the “Events and Publications” tab on the investor relations section of the Centessa Pharmaceuticals website at https://investors.centessa.com/events-presentations. About Centessa Pharmaceuticals Centessa Pharmaceuticals, plc is a clinical-stage pharmaceutical company with a mission to discover, develop and ultimately deliver medicines that are transformational for patients. | GlobeNewsWire | 2026-02-03 08:00:00 |
| This Fund Locked In Gains With a $14.5 Million Biotech Exit Amid a Staggering Stock Rally | Tanager Wealth Management exited its entire CNTA position, reducing holdings by 598,044 shares in the fourth quarter. As a result, the quarter-end position value decreased by $14.50 million, reflecting both the share sale and stock price movement. | The Motley Fool | 2026-02-01 19:09:23 |
| Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Receives Consensus Rating of “Moderate Buy” from Analysts | Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ: CNTA - Get Free Report) has earned an average rating of "Moderate Buy" from the thirteen analysts that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, eleven have issued a buy rating and one has given a strong | Defense World | 2026-02-01 02:44:44 |
| Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual Meeting | Antidepressive effects and enhanced wakefulness were observed with OX2R activation in established animal model of major depressive disorder Antidepressive effects and enhanced wakefulness were observed with OX2R activation in established animal model of major depressive disorder | GlobeNewsWire | 2026-01-14 17:00:00 |
| Nxera Pharma to Receive US$3.6 Million in Milestone Payment Pursuant to Research Collaboration with Centessa | Tokyo, Japan and Cambridge, UK, 13 January 2026 - Nxera Pharma Co. , Ltd. ("Nxera" or "the Company"; TSE 4565) notes that Centessa Pharmaceuticals has achieved an early development milestone associated with its investigational, orally administered, highly potent and selective orexin receptor 2 (OX2R) agonist, ORX142, in development for the treatment of neurological and neurodegenerative disorders. | Globe News Wire | 2026-01-13 03:09:00 |
| Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Given Average Rating of “Moderate Buy” by Brokerages | Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ: CNTA - Get Free Report) has received an average rating of "Moderate Buy" from the twelve ratings firms that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, ten have issued a buy recommendation and one has issued a strong buy recommendation | Defense World | 2026-01-07 01:30:45 |
| Critical Review: Centessa Pharmaceuticals (NASDAQ:CNTA) & Universe Pharmaceuticals (NASDAQ:UPC) | Centessa Pharmaceuticals (NASDAQ: CNTA - Get Free Report) and Universe Pharmaceuticals (NASDAQ: UPC - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, risk, profitability, analyst recommendations and valuation. Risk and Volatility Centessa Pharmaceuticals has a beta | Defense World | 2025-12-22 01:32:52 |
| Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Receives Consensus Recommendation of “Buy” from Analysts | Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ: CNTA - Get Free Report) has been assigned an average recommendation of "Buy" from the thirteen analysts that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, ten have assigned a buy rating and two have assigned a strong | Defense World | 2025-12-13 01:16:58 |
| Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications | Mario Alberto Accardi PhD, President and founder of Centessa's Orexin Program, appointed Chief Executive Officer and member of the Board of Directors Mario Alberto Accardi PhD, President and founder of Centessa's Orexin Program, appointed Chief Executive Officer and member of the Board of Directors | GlobeNewsWire | 2025-12-11 07:00:00 |
| What One Fund's Sale of Centessa Stock Signals About the Fast-Rising Biotech Company | San Francisco-based 5AM Venture Management sold 150,000 CNTA shares in the third quarter. Despite the sale, the stock's sharp rally last quarter led the fund's net position value in CNTA to increase by $5.6 million. | The Motley Fool | 2025-11-29 13:48:38 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| SC 13G/A | 2026-02-17 | 2026-02-17 | View Filing |
| 8-K | 2026-02-13 | 2026-02-13 | View Filing |
| SC 13G/A | 2026-02-06 | 2026-02-06 | View Filing |
| SC 13G/A | 2026-02-05 | 2026-02-05 | View Filing |
| 4 | 2026-02-03 | 2026-02-03 | View Filing |
| 4 | 2026-02-03 | 2026-02-03 | View Filing |
| 4 | 2026-02-03 | 2026-02-03 | View Filing |
| 4 | 2026-02-03 | 2026-02-03 | View Filing |
| 4 | 2026-02-03 | 2026-02-03 | View Filing |
| 4 | 2026-02-03 | 2026-02-03 | View Filing |
| 4 | 2026-02-03 | 2026-02-03 | View Filing |
| 4 | 2026-02-03 | 2026-02-03 | View Filing |
| 8-K/A | 2026-01-07 | 2026-01-06 | View Filing |
| 8-K | 2025-12-11 | 2025-12-11 | View Filing |
| 4 | 2025-12-09 | 2025-12-09 | View Filing |
| 4 | 2025-12-08 | 2025-12-08 | View Filing |
| SC 13D/A | 2025-11-28 | 2025-11-28 | View Filing |
| 8-K | 2025-11-24 | 2025-11-24 | View Filing |
| 424B5 | 2025-11-24 | 2025-11-24 | View Filing |
| 4 | 2025-11-18 | 2025-11-18 | View Filing |
| 4 | 2025-11-18 | 2025-11-18 | View Filing |
| SC 13D/A | 2025-11-17 | 2025-11-17 | View Filing |
| SC 13G | 2025-11-14 | 2025-11-14 | View Filing |
| 4 | 2025-11-13 | 2025-11-13 | View Filing |
| SC 13G/A | 2025-11-13 | 2025-11-13 | View Filing |
| 8-K | 2025-11-13 | 2025-11-13 | View Filing |
| 424B5 | 2025-11-13 | 2025-11-13 | View Filing |
| 424B5 | 2025-11-12 | 2025-11-12 | View Filing |
| SC 13G | 2025-11-05 | 2025-11-05 | View Filing |
| 10-Q | 2025-11-05 | 2025-11-05 | View Filing |
| 8-K | 2025-11-05 | 2025-11-05 | View Filing |
| 4 | 2025-11-03 | 2025-11-03 | View Filing |
| 4 | 2025-10-27 | 2025-10-27 | View Filing |
| 4 | 2025-10-16 | 2025-10-16 | View Filing |
| 4 | 2025-09-24 | 2025-09-24 | View Filing |
| 4 | 2025-09-16 | 2025-09-16 | View Filing |
| 4 | 2025-09-15 | 2025-09-15 | View Filing |
| 4 | 2025-09-11 | 2025-09-11 | View Filing |
| 4 | 2025-09-11 | 2025-09-11 | View Filing |
| 4 | 2025-09-11 | 2025-09-11 | View Filing |
| 4 | 2025-08-15 | 2025-08-15 | View Filing |
| SC 13G/A | 2025-08-12 | 2025-08-12 | View Filing |
| 10-Q | 2025-08-12 | 2025-08-12 | View Filing |
| 8-K | 2025-08-12 | 2025-08-12 | View Filing |
| 4 | 2025-08-01 | 2025-08-01 | View Filing |
| 4 | 2025-07-30 | 2025-07-30 | View Filing |
| 4 | 2025-07-25 | 2025-07-25 | View Filing |
| 4 | 2025-07-21 | 2025-07-21 | View Filing |
| 4 | 2025-07-17 | 2025-07-17 | View Filing |
| 4 | 2025-06-25 | 2025-06-25 | View Filing |
| 4 | 2025-06-25 | 2025-06-25 | View Filing |
| 4 | 2025-06-25 | 2025-06-25 | View Filing |
| 4 | 2025-06-24 | 2025-06-24 | View Filing |
| 4 | 2025-06-24 | 2025-06-24 | View Filing |
| 4 | 2025-06-24 | 2025-06-24 | View Filing |
| 4 | 2025-06-24 | 2025-06-24 | View Filing |
| 4 | 2025-06-24 | 2025-06-24 | View Filing |
| 4 | 2025-06-24 | 2025-06-24 | View Filing |
| 3 | 2025-06-24 | 2025-06-24 | View Filing |
| 4 | 2025-06-20 | 2025-06-20 | View Filing |
| 8-K | 2025-06-20 | 2025-06-20 | View Filing |
| 8-K | 2025-06-17 | 2025-06-17 | View Filing |
| 4 | 2025-06-03 | 2025-06-03 | View Filing |
| 3 | 2025-06-03 | 2025-06-03 | View Filing |
| 8-K | 2025-05-29 | 2025-05-29 | View Filing |
| DEFA14A | 2025-05-28 | 2025-05-28 | View Filing |
| 4 | 2025-05-27 | 2025-05-27 | View Filing |
| 4 | 2025-05-20 | 2025-05-20 | View Filing |
| 4 | 2025-05-19 | 2025-05-19 | View Filing |
| 10-Q | 2025-05-14 | 2025-05-14 | View Filing |
| 8-K | 2025-05-14 | 2025-05-14 | View Filing |
| SC 13G | 2025-05-12 | 2025-05-12 | View Filing |
| ARS | 2025-05-06 | 2025-05-06 | View Filing |
| DEF 14A | 2025-05-06 | 2025-05-06 | View Filing |
| 4 | 2025-05-02 | 2025-05-02 | View Filing |
| 4 | 2025-04-29 | 2025-04-29 | View Filing |
| 4 | 2025-04-25 | 2025-04-25 | View Filing |
| 4 | 2025-04-22 | 2025-04-22 | View Filing |
| PRE 14A | 2025-04-22 | 2025-04-22 | View Filing |
| 4 | 2025-03-26 | 2025-03-26 | View Filing |
| S-8 | 2025-03-24 | 2025-03-24 | View Filing |
| 10-K | 2025-03-24 | 2025-03-24 | View Filing |
| 8-K | 2025-03-24 | 2025-03-24 | View Filing |
| 4 | 2025-03-21 | 2025-03-21 | View Filing |
| 4 | 2025-03-19 | 2025-03-19 | View Filing |
| 4 | 2025-03-19 | 2025-03-19 | View Filing |
| 4 | 2025-02-26 | 2025-02-26 | View Filing |
| 8-K | 2025-02-21 | 2025-02-21 | View Filing |
| 4 | 2025-02-20 | 2025-02-20 | View Filing |
| 4 | 2025-02-19 | 2025-02-19 | View Filing |
| 10-Q/A | 2025-02-14 | 2025-02-14 | View Filing |
| 4 | 2025-02-10 | 2025-02-10 | View Filing |
| 4 | 2025-02-04 | 2025-02-04 | View Filing |
| 4 | 2025-02-04 | 2025-02-04 | View Filing |
| 4 | 2025-02-04 | 2025-02-04 | View Filing |
| 4 | 2025-02-04 | 2025-02-04 | View Filing |
| 4 | 2025-02-04 | 2025-02-04 | View Filing |
| 4 | 2025-02-04 | 2025-02-04 | View Filing |
| 4 | 2025-02-04 | 2025-02-04 | View Filing |
| 4 | 2025-02-04 | 2025-02-04 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Larry Williams PercentR Strategy | 47.56% | 1.02 | 185 | 0.04 | 0.07 | 44.94 |
| Neural Forcast | 43.18% | 1.01 | 730 | 0.04 | 0.06 | 40.57 |
| Williams PercentR Strategy | 31.76% | 1.01 | 328 | 0.02 | 0.04 | 29.14 |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxx | xxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | x | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xxx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xxx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | x | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | x | xxxx |
| xxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxx | xxxxx |